SEC v. Patel: Market Manipulation Through Spoofing and Layering, Federal Charges, and Defense Considerations
The SEC charged day trader Harsh Patel with manipulating more than 400 securities through spoofing and layering. Analysis of the three federal counts, their elements under SDNY authority, and defense considerations including scienter, non-bona fide order characterization, liability causation, and parallel criminal exposure.
Federal Healthcare Fraud and Illegal Prescribing Charges: Intent, Medical Necessity, and Defense Strategies
Missouri physician indicted on 38 federal counts combining healthcare fraud with illegal prescribing of Adderall, benzodiazepines, and hydrocodone. Analysis of the government's burden on intent after Ruan v. United States, medical necessity defenses for non-opioid controlled substances, supervision fraud theories under 18 U.S.C. § 1347, and why trial readiness matters in dual-theory prosecutions. By former DOJ ARPO Strike Force director.
OneCoin Fraud Victim Claims: How to File for DOJ Compensation Before the June 2026 Deadline
The DOJ opened a $40 million compensation process for OneCoin fraud victims. Claims must be filed by June 30, 2026 at onecoinremission.com. This guide explains who is eligible under 28 C.F.R. Part 9, what documentation is required, how recovery amounts are calculated, and the criminal exposure risks for OneCoin promoters.
FDA Warning Letters on Exosome Products | Regulatory & Criminal Defense
FDA warning letters to exosome manufacturers cite unapproved drugs, unlicensed biologics, and misbranded products under the FD&C Act and PHS Act. Analysis of enforcement trends from 2024 through 2026, criminal prosecution risks, and the regulatory framework for exosome products. Defense by former senior DOJ officials.
CFTC Oil Futures Investigation: Insider Trading Charges and Defense
Former DOJ Fraud Section prosecutors analyze the CFTC oil futures investigation, Tag 50 exchange data, commodities fraud charges under the CEA, and defenses.
Home Health Certification in Federal Fraud Cases: OASIS, Homebound Status, Face-to-Face Encounter
Analysis of the Medicare home health certification process in federal criminal fraud cases. Covers the face-to-face encounter under 42 C.F.R. 424.22, OASIS assessment scoring under PDGM, homebound status certification, CMS-485 physician certification, LCD compliance, and defense strategies including cross-examination of beneficiary witnesses who received undisclosed kickback payments. By former DOJ Fraud Section prosecutors.
DOJ Creates the National Fraud Enforcement Division: What It Means for Federal Procurement Fraud Defense
On April 7, 2026, Acting Attorney General Todd Blanche established the National Fraud Enforcement Division. Analysis of the new division, recent criminal procurement fraud cases, the statutes DOJ uses, and the key defenses available to individuals facing investigation or indictment.
Operation Never Say Die: Federal Hospice Fraud Arrests and CMS Payment Suspensions
Eight defendants arrested and 221 hospice providers suspended in Operation Never Say Die. Analysis of the federal charges, CMS payment suspension procedures under 42 C.F.R. 405.371, and the strategic risks of responding to a suspension notice while a parallel DOJ criminal investigation may be active.
Clawback Demands: Coming soon from the Goliath Ventures Case
Clawback defense for Goliath Ventures investors, vendors, and professionals. Scott Armstrong and Drew Bradylyons, founders of Armstrong & Bradyylons PLLC and former senior DOJ officials, explain the receiver's theories, challenges, and strongest available defenses.
Injection Fraud Is a Federal Enforcement Priority: Charges, Defenses, and What Providers Need to Know
DOJ and HHS-OIG are aggressively targeting injection fraud in 2025 and 2026. Facet joint injections, Botox, trigger point injections, and epidural steroid injections billed to Medicare are under direct federal scrutiny. This guide covers the key federal charges, defenses, and billing codes at issue. Armstrong & Bradylyons PLLC defends physicians and healthcare executives in federal injection fraud investigations nationwide.
Hospice Fraud: On the Law-Enforcement Horizon
Federal hospice fraud investigations are escalating in 2025 and 2026. Scott Armstrong and Drew Bradylyons, two former Assistant Chiefs at DOJ’s Fraud Section, explain the scrutiny, investigations, and charges that hospice executives and certifying physicians face in these cases.